Clinical trial
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
NCT01249027 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
- Lead sponsor
- Abbott Medical Devices
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- January 31, 2017
- Enrollment
- 2,605 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
angioplasty, chronic coronary occlusion, coronary artery disease, coronary artery stenosis, coronary disease, coronary restenosis, myocardial ischemia, stent thrombosis, vascular disease